导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.78% | 3981/4773 |
| 近一周 | -2.69% | 4157/5465 |
| 近一月 | -2.88% | 1984/5421 |
| 近一季 | -2.54% | 1415/5231 |
| 近半年 | -4.57% | 2867/4920 |
| 近一年 | -16.14% | 3811/4394 |
| 近两年 | 31.32% | 2228/2954 |
| 近三年 | 11.28% | 1722/2253 |
| 成立以来 | 1.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.98% 4687/4961 |
9.16% 2500/5312 |
- - |
- - |
| 2025 | 4.04% 3077/4813 |
-6.94% 3412/3635 |
4.48% 748/4076 |
11.43% 3164/4524 |
-3.97% 3368/4813 |
| 2024 | 29.50% 128/3463 |
-4.86% 1784/2808 |
-8.42% 2235/3014 |
41.38% 59/3129 |
5.13% 636/3463 |
| 2023 | 4.41% 230/2656 |
4.20% 1022/2280 |
-2.68% 630/2385 |
7.66% 29/2515 |
-4.37% 984/2655 |
| 2022 | -25.59% 1329/2207 |
-18.42% 1336/1919 |
2.06% 1368/2016 |
-15.86% 1358/2113 |
6.22% 381/2208 |
| 2021 | -1.95% 830/1822 |
-14.52% 1178/1255 |
7.20% 693/1330 |
4.92% 310/1466 |
1.99% 728/1822 |
| 2020 | - - |
- - |
- - |
6.10% 874/1164 |
1.57% 1022/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信中证全指证券公司ETF VS. 长安沪深300非周期A(740101) |